Job Watch

Novel Synthetic Nucleic Acid Technology Development (R43/R44)( Clinical Trial not allowed)

Funding Opportunity RFA-HG-20-016 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits R43/R44 grant applications from small businesses to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Large progress in this area has the potential to catalyze scientific advances relevant to the mission of NIH, NHGRI and the field of genomics.

Novel Synthetic Nucleic Acid Technology Development (R21 Clinical Trial not allowed)

Funding Opportunity RFA-HG-20-015 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits R21 grant applications to develop novel technologies that will enable substantive (no less than one order of magnitude) improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs at reasonable and decreased costs. Applicants may propose to develop novel complete synthesis and/or synthetic constructs systems, investigate challenges underlying key novel system components, or propose substantive improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.

Novel Synthetic Nucleic Acid Technology Development (R01 Clinical Trial not allowed)

Funding Opportunity RFA-HG-20-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits R01 grant applications to develop novel technologies that will enable no less than one order of magnitude improvement in synthetic nucleic acids. The goal is to improve the quality, capabilities and efficiency of nucleic acid synthesis and synthetic constructs (e.g., longer oligonucleotide and synthetic construct lengths, faster turn-around times, greater accuracy, incorporation of modified bases, higher-throughput, etc.) at reasonable and decreased costs with the anticipation that major advances in any of these and related areas would make significant contributions to the mission of NIH, NHGRI and the field of genomics, including to many of NHGRIs other technology development goals.

Patient-oriented Research to Mitigate Health Disparities and Lessen the Burden of Chronic Diseases Within the Mission of NIDDK (R01 Clinical Trial Optional)

Funding Opportunity RFA-DK-20-015 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement invites applications to conduct patient-oriented clinical research studies designed to develop strategies to mitigate health disparities in people with one or more chronic diseases or conditions within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Populations of interest include those disproportionately burdened with multiple chronic conditions and/or disparities in social, behavioral and/or biological risk factors. Only studies that involve interaction with human participants will be considered appropriate for this FOA.

Computational Chemistry and Biology Opportunities at D. E. Shaw Research

The Science Jobs - Bioinformatics - Wed, 2020-03-18 09:10
D. E. Shaw Research is seeking exceptional computational chemists and biologists, as well as other computational scientists with a track record of extraordinary achievement, to
Categories: Job Watch

EMBL: Data Platform Coordinator

New Scientist - Bioinformatics - Tue, 2020-03-17 05:35
Competitive Salary: EMBL: Data Platform Coordinator Location: Cambridge, Cambridgeshire, England
Categories: Job Watch

Pages

Subscribe to Anil Jegga aggregator - Job Watch